Aktienanalyse zu Seaport Therapeutics Inc (SPTX)SPTXSeaport Therapeutics Inc

Seaport Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. Its product candidate, GlyphAllo (SPT-300 or Glyph Allopregnanolone), is a novel, Glyphed oral prodrug of allopregnanolone, an endogenous molecule that has been clinically validated in third-party trials for the treatment of postpartum depression. GlyphAgo (SPT-320 or Glyph Agomelatine), is a novel, Glyphed oral prodrug of agomelatine, a clinically validated anxiolytic and antidepressant that is approved for the treatment of generalized anxiety disorder. It is also advancing Glyph2BLS (SPT-348 or Glyph 2-bromo-LSD), a novel, Glyphed oral prodrug of the non-hallucinogenic LSD analog 2-bromo-LSD, in preclinical studies for depressive disorders. GlyphAllo is designed to overcome the bioavailability limitations of allopregnanolone and be durable in MDD. It operates in the Healthcare sector.

Seaport Therapeutics, Inc. (SPTX) is a good buy right now due to its strong analyst ratings and promising clinical trial results. The stock is currently priced at $17.83, with a forward P/E ratio of 0, indicating no earnings expectations, which can be favorable for growth potential. Analysts have set a price target averaging $37.13, suggesting a substantial upside of 72.61%. The recent positive Phase 1 results for GlyphAllo further enhance its growth prospects, although the company reported a significant net loss of $62.6 million in Q2 2026, which remains a key risk.